UCB Amendment to Revolving Credit Facility
Brussels, Belgium, 1 December 2010 - UCB announced today that the amendment and restatement of its original EUR 1.5 billion revolving credit facility signed December 2009 has been successfully closed, with significant oversubscription.
| Detlef Thielgen, Chief Financial Officer of UCB, comments, "We are very pleased to have successfully improved the main terms of our existing facility. The fact that all existing banks have signed up to this amendment, underscores the confidence which the loan markets have in UCB." |
The amendment reduces the facility size to EUR 1.0 billion, extends the maturity from 2012 to 2015 and brings the loan in line with the improved current investment grade terms.
UCB appointed BNP Paribas Fortis, Commerzbank AG and Mizuho Corporate Bank as Joint Co-Ordinator MLA (Mandated Lead Arranger) Bookrunners for the restated facility.
For further clarifications please contact:
Stephan Janes, Head of Debt Origination
Mizuho Corporate Bank, T + 44 20 7012 4393
Claus Mueller, Director - Sales
Mizuho Corporate Bank, T + 44 20 7012 4256
André van der Toorn, Treasury & Risk Management UCB
T + 32.2.559.9709, andre.vandertoorn@ucb.com
Antje Witte, Investor Relations UCB
T +32.2.559.9414, antje.witte@ucb.com
Richard Simpson, Investor Relations, UCB
T+32.2.559.9494, richard.simpson@ucb.com
Michael Tuck-Sherman, Investor Relations, UCB
T +32.2.559.9712, michael.tuck-sherman@ucb.com
About UCB
UCB, Brussels, Belgium (www.ucb.com) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With more than 8 000 people in about 40 countries, the company generated revenue of EUR 3.1 billion in 2009. UCB is listed on Euronext Brussels (symbol: UCB).
Forward looking statements
This press release contains forward-looking statements based on current plans, estimates and beliefs of management. Such statements are subject to risks and uncertainties that may cause actual results to be materially different from those that may be implied by such forward-looking statements contained in this press release. Important factors that could result in such differences include: changes in general economic, business and competitive conditions, effects of future judicial decisions, changes in regulation, exchange rate fluctuations and hiring and retention of its employees.
Asset Download
Stay up-to-date on the latest news and information from UCB